mustangbio.com (MBIO) Long-Term Debt to Capital Ratio

Symbol and logo of brand Mustang Bio Inc (MBIO)

The long-term debt-to-equity structure of Mustang Bio, Inc. (MBIO) reflects a dependence on the complexity of individualized CAR-T therapy production. The 0.00 mark serves as a key metric capturing the financial leverage. Stability of these indicators relies on rigorous cryo-logistics for biomaterials. However, a deficit of R&D funding and strict FDA regulations regarding genome editing limit the expansion of the client base.

mustangbio.com (MBIO): Long-Term Debt to Equity from 07/04/2022 to 10/31/2026
Core merchandise of mustangbio.com

This indicator determines the ratio of long-term borrowings to equity, measuring the degree of the business's financial autonomy. By analyzing the long-term financial leverage ratio, an investor distinguishes a sustainable reduction in debt load from short-term liquidity fluctuations. The current calculated value of the metric is 0.00. Minimizing borrowed capital reduces default risks, which allows Mustang Bio, Inc. (MBIO) to focus on retaining scarce R&D specialists through stock option programs.

Key competitors

Long-Term Debt to Capital Ratio TEM (Tempus)|Long-Term Debt to Equity Qiagen Group (QGEN)|Isis Pharmaceuticals - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital RGEN (Repligen Corporation)|Long-Term Debt to Capital aviditybiosciences.com RNA|CRSP - Long-Term Debt to Equity|GeneDx Holdings (WGS) - Long-Term Debt to Equity Ratio|RARE (Ultragenyx Pharma) - Long-Term Debt to Equity Ratio|Beam Tx (BEAM) - Long-Term Debt to Capital|Long-Term Debt to Equity Sarepta Therapeutics, Inc.|twistbioscience.com (TWST) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ratio TXG (10x Genomics)|Long-Term Loans to Capital Ratio NTLA|Long-Term Debt to Capital STOK (Stoke)|Long-Term Debt to Capital BioLife BLFS|WVE - Long-Term Debt to Equity|MAZE (mazetx.com) - Long-Term Debt to Capital Ratio|SION: Long-Term Debt to Capital|Long-Term Indebtedness to Equity Prime Medicine Inc PRME|Long-Term Debt to Equity Ratio TSHA|QURE: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital MGTX|Long-Term Debt to Equity RGNX (regenxbio.com)|Long-Term Debt to Capital SLDB (Solid Biosciences)|Ratio of Long-Term Indebtedness to Capital Ocugen Inc (OCGN)|PACB - Long-Term Debt to Equity|Long-Term Liabilities to Capital Benitec Corp|DSGN (Design Therapeutics) - Long-Term Debt to Equity Ratio|rocketpharma.com - Long-Term Debt to Capital Coefficient|FDMT (4D Molecular Therapeutics, Inc.) - Long-Term Debt to Capital|Lexeo (LXEO) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Korro Bio, Inc. (KRRO)|Editas Corp - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital SLN (Silence Therapeutics)|PRQR - Long-Term Debt to Equity Ratio|CDXS: Long-Term Debt to Equity Ratio|Ratio of Long-Term Indebtedness to Capital Sangamo Therapeutics Inc. SGMO|nautilus.bio (NAUT) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Metagenomi Therapeutics|DTIL (Precision BioSciences) - Long-Term Debt to Capital|Long-Term Debt to Equity GBIO|Long-Term Debt to Capital BOLD|Ratio of Long-Term Indebtedness to Capital exicuretx.com|Long-Term Debt to Equity Imunon IMNN|Phio Pharmaceuticals Corp (PHIO) - Long-Term Liabilities to Capital|TransCode - Long-Term Debt to Capital|BNGO (Bionano Genomics, Inc.) - Long-Term Debt to Capital Ratio|Applied DNA Sciences, Inc. (APDN) - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio BLUE|IPA (ImmunoPrecise Antibodies Ltd) - Long-Term Debt to Capital|Long-Term Debt to Capital Omega Therapeutics Corp|Long-Term Debt to Equity Singular Genomics Systems (OMIC)|Long-Term Debt to Equity Ratio regulusrx.com RGLS|Syros Pharmaceuticals, Inc. - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Telesis Bio Inc. TBIO|TCON - Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital Unity Biotechnology, Inc UBX